MAKO Mako Surgical Corp. (MM)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  October 1, 2013

 

MAKO Surgical Corp.

(Exact name of registrant as specified in its charter)

 

Delaware	001-33966	20-1901148
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

 

2555 Davie Road

Fort Lauderdale, Florida 33317

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (954) 927-2044

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 1.01

Entry into a Material Definitive Agreement.

 

On October 1, 2013, MAKO Surgical Corp. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Pipeline Biomedical Holdings, Inc. (“Pipeline”). Under the terms of the Purchase Agreement, the Company will purchase substantially all of Pipeline’s business dedicated to the design, development, manufacture and commercialization of orthopedic devices and related instruments for use with robotic devices and manual medical procedures (the “Transaction”). The Company expects to close the Transaction on or before October 4, 2013, subject to the satisfaction of customary closing conditions.

 

The purchase price for the Transaction consists of a credit for a cash down payment previously paid to Pipeline in the amount of $2,500,000 and the Company’s issuance to Pipeline at closing of an aggregate of 3,953,771 unregistered shares of common stock of the Company.

 

The Purchase Agreement contains customary representations, warranties, covenants and indemnities. The closing of the Transaction is subject to various conditions, including receipt of third party consents and approvals and other customary closing conditions. The Purchase Agreement also provides that the Company will enter into employment and consulting arrangements with certain key employees of the acquired business at closing.

 

The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement, which is filed as Exhibit 2.1 hereto and incorporated herein by reference.

 

Item 8.01

Other Events.

 

On October 2, 2013, the Company issued a press release announcing the entry into the Purchase Agreement. A copy of the press release is furnished herewith as Exhibit 99.1 hereto and is incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit 2.1

Asset Purchase Agreement, dated October 1, 2013, by and between Pipeline Biomedical Holdings, Inc. and MAKO Surgical Corp.†

 

Exhibit 99.1

Press Release dated October 2, 2013.

 

†Schedules and other similar attachments have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company hereby undertakes to furnish supplementally copies of any of the omitted schedules and attachments upon request by the U.S. Securities and Exchange Commission.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	MAKO SURGICAL CORP.
Date:  October 2, 2013
	/s/  Maurice R. Ferré, M.D.
	Maurice R. Ferré, M.D. President and Chief Executive Officer